Emergent Biosolutions Slide After Widening 4Q Loss, Logging Lower Revenue

Dow Jones

02/27

By Connor Hart

Shares of Emergent Biosolutions fell after the company widened its loss and logged lower revenue during the fourth quarter.

The stock sank 23%, to $8.58, in premarket trading Friday. Through Thursday's close, shares are up 48% over the past year.

The company after Thursday's closing bell posted a loss of $54.6 million, or $1.04 a share, compared with a loss of $31.3 million, or 58 cents a share, a year earlier.

Stripping out one-time items, Emergent reported a loss of 43 cents a share.

Revenue fell to $148.7 million, from $194.7 million in the same quarter last year.

Chief Executive Joe Papa said the company made progress executing on its multi-year turnaround strategy last year, citing improved operating margins, increased cash flow and lower leverage.

Looking forward, the company in 2026 aims to expand its international operations, pursue growth opportunities and remain disciplined on operational efficiencies, he added.

For the current quarter, Emergent guided for revenue of $135 million to $155 million.

For the year, the company forecast a net loss between $10 million and $30 million, or earnings of $25 million to $45 million on an adjusted basis. Revenue is projected to come in between $720 million and $760 million, the midpoint of which is below the $742.9 million in revenue the company posted last year.

Write to Connor Hart at connor.hart@wsj.com

(END) Dow Jones Newswires

February 27, 2026 06:51 ET (11:51 GMT)

Copyright (c) 2026 Dow Jones & Company, Inc.

應版權方要求，你需要登入查看該內容

登入 / 註冊

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2614583016"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2614583016\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2614583016?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-02-27 19:51","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2614583016","market":"nz","top_or_hot":-1,"title":"Emergent Biosolutions Slide After Widening 4Q Loss, Logging Lower Revenue","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  By Connor Hart \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Shares of <a href=\"https://laohu8.com/S/EBS\">Emergent Biosolutions</a> fell after the company widened its loss and logged lower revenue during the fourth quarter. \n</p>\n<p>\n  The stock sank 23%, to $8.58, in premarket trading Friday. Through Thursday's close, shares are up 48% over the past year. \n</p>\n<p>\n  The company after Thursday's closing bell posted a loss of $54.6 million, or $1.04 a share, compared with a loss of $31.3 million, or 58 cents a share, a year earlier. \n</p>\n<p>\n  Stripping out one-time items, Emergent reported a loss of 43 cents a share. \n</p>\n<p>\n  Revenue fell to $148.7 million, from $194.7 million in the same quarter last year. \n</p>\n<p>\n  Chief Executive Joe Papa said the company made progress executing on its multi-year turnaround strategy last year, citing improved operating margins, increased cash flow and lower leverage. \n</p>\n<p>\n  Looking forward, the company in 2026 aims to expand its international operations, pursue growth opportunities and remain disciplined on operational efficiencies, he added. \n</p>\n<p>\n  For the current quarter, Emergent guided for revenue of $135 million to $155 million. \n</p>\n<p>\n  For the year, the company forecast a net loss between $10 million and $30 million, or earnings of $25 million to $45 million on an adjusted basis. Revenue is projected to come in between $720 million and $760 million, the midpoint of which is below the $742.9 million in revenue the company posted last year. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Connor Hart at connor.hart@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  February 27, 2026 06:51 ET (11:51 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Emergent Biosolutions Slide After Widening 4Q Loss, Logging Lower Revenue</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nEmergent Biosolutions Slide After Widening 4Q Loss, Logging Lower Revenue\n</h2>\n<h4 class=\"meta\">\n<div class=\"head\" \">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time smaller\">2026-02-27 19:51</p>\n</div>\n</div>\n</h4>\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  By Connor Hart \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Shares of <a href=\"https://laohu8.com/S/EBS\">Emergent Biosolutions</a> fell after the company widened its loss and logged lower revenue during the fourth quarter. \n</p>\n<p>\n  The stock sank 23%, to $8.58, in premarket trading Friday. Through Thursday's close, shares are up 48% over the past year. \n</p>\n<p>\n  The company after Thursday's closing bell posted a loss of $54.6 million, or $1.04 a share, compared with a loss of $31.3 million, or 58 cents a share, a year earlier. \n</p>\n<p>\n  Stripping out one-time items, Emergent reported a loss of 43 cents a share. \n</p>\n<p>\n  Revenue fell to $148.7 million, from $194.7 million in the same quarter last year. \n</p>\n<p>\n  Chief Executive Joe Papa said the company made progress executing on its multi-year turnaround strategy last year, citing improved operating margins, increased cash flow and lower leverage. \n</p>\n<p>\n  Looking forward, the company in 2026 aims to expand its international operations, pursue growth opportunities and remain disciplined on operational efficiencies, he added. \n</p>\n<p>\n  For the current quarter, Emergent guided for revenue of $135 million to $155 million. \n</p>\n<p>\n  For the year, the company forecast a net loss between $10 million and $30 million, or earnings of $25 million to $45 million on an adjusted basis. Revenue is projected to come in between $720 million and $760 million, the midpoint of which is below the $742.9 million in revenue the company posted last year. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Connor Hart at connor.hart@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  February 27, 2026 06:51 ET (11:51 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2614583016","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2614583016","pubTimestamp":1772193060,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Shares of Emergent Biosolutions fell after the company widened its loss and logged lower revenue during the fourth quarter.The stock sank 23%, to $8.58, in premarket trading Friday. Through Thursday's close, shares are up 48% over the past year.The company after Thursday's closing bell posted a loss of $54.6 million, or $1.04 a share, compared with a loss of $31.3 million, or 58 cents a share, a year earlier.Stripping out one-time items, Emergent reported a loss of 43 cents a share.Revenue fell to $148.7 million, from $194.7 million in the same quarter last year.Chief Executive Joe Papa said the company made progress executing on its multi-year turnaround strategy last year, citing improved operating margins, increased cash flow and lower leverage.For the year, the company forecast a net loss between $10 million and $30 million, or earnings of $25 million to $45 million on an adjusted basis. Revenue is projected to come in between $720 million and $760 million, the midpoint of which is","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","BK4583":"猴痘概念","EBS":"Emergent Biosolutions"},"translate_title":"Emergent Biosolutions在第四季度亏损扩大、收入下降后下滑","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"EBS":0.9},"content_text":"By Connor Hart \n\n\n \n\n\n  Shares of Emergent Biosolutions fell after the company widened its loss and logged lower revenue during the fourth quarter. \n\n\n  The stock sank 23%, to $8.58, in premarket trading Friday. Through Thursday's close, shares are up 48% over the past year. \n\n\n  The company after Thursday's closing bell posted a loss of $54.6 million, or $1.04 a share, compared with a loss of $31.3 million, or 58 cents a share, a year earlier. \n\n\n  Stripping out one-time items, Emergent reported a loss of 43 cents a share. \n\n\n  Revenue fell to $148.7 million, from $194.7 million in the same quarter last year. \n\n\n  Chief Executive Joe Papa said the company made progress executing on its multi-year turnaround strategy last year, citing improved operating margins, increased cash flow and lower leverage. \n\n\n  Looking forward, the company in 2026 aims to expand its international operations, pursue growth opportunities and remain disciplined on operational efficiencies, he added. \n\n\n  For the current quarter, Emergent guided for revenue of $135 million to $155 million. \n\n\n  For the year, the company forecast a net loss between $10 million and $30 million, or earnings of $25 million to $45 million on an adjusted basis. Revenue is projected to come in between $720 million and $760 million, the midpoint of which is below the $742.9 million in revenue the company posted last year. \n\n\n \n\n\n  Write to Connor Hart at connor.hart@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  February 27, 2026 06:51 ET (11:51 GMT)\n\n\n  Copyright (c) 2026 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"dataReport,merge","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}